Identification of Hck Inhibitors As Hits for the Development of Antileukemia and Anti-HIV Agents

Cristina Tintori, Ilaria Laurenzana, Francesco LaRocca, Federico Falchi, Fabio Carraro, Alba Ruiz, José A. Esté, Miroslava Kissova, Emmanuele Crespan, Giovanni Maga, Mariangela Biava, Chiara Brullo, Silvia Schenone, Maurizio Botta

Research output: Contribution to journalArticlepeer-review


Hematopoietic cell kinase (Hck) is a member of the Src family of non-receptor protein tyrosine kinases. High levels of Hck are associated with drug resistance in chronic myeloid leukemia. Furthermore, Hck activity has been connected with HIV-1. Herein, structure-based drug design efforts were aimed at identifying novel Hck inhibitors. First, an in-house library of pyrazolo[3,4-d]pyrimidine derivatives, which were previously shown to be dual Abl and c-Src inhibitors, was analyzed by docking studies within the ATP binding site of Hck to select the best candidates to be tested in a cell-free assay. Next, the same computational protocol was applied to screen a database of commercially available compounds. As a result, most of the selected compounds were found active against Hck, with Ki values ranging from 0.14 to 18.4μM, confirming the suitability of the computational approach adopted. Furthermore, selected compounds showed an interesting antiproliferative activity profile against the human leukemia cell line KU-812, and one compound was found to block HIV-1 replication at sub-toxic concentrations.

Original languageEnglish
Pages (from-to)1353-1360
Number of pages8
Issue number8
Publication statusPublished - Aug 2013


  • Docking
  • Hck
  • HIV-1
  • Kinases
  • Leukemia

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry
  • Molecular Medicine


Dive into the research topics of 'Identification of Hck Inhibitors As Hits for the Development of Antileukemia and Anti-HIV Agents'. Together they form a unique fingerprint.

Cite this